Overview
Substantial evidence exists to support the safety and efficacy of CGM in adult and pediatric populations. Though challenges to adoption and use remain, newer generations of CGM with improved accuracy, factory calibration, and fingerstick replacement are decreasing burdens and improving efficacy. Guidelines for CGM use are progressing to recommend its use across the spectrum of people with diabetes.
The IDEA Project is a major educational initiative that will change the way CGM data is interpreted and used in diabetes care by health care professionals and by patients with diabetes.
IDEA Collaborative Organizations:
- American Association of Clinical Endocrinology (AACE)
- Association of Diabetes Care & Education Specialists (ADCES)
- American College of Clinical Pharmacy (ACCP)
- American Society of Endocrine Physician Assistants (ASEPA)
- International Diabetes Center (IDC)
- American Academy of Physician Assistants (AAPA)
- Diabetes Patient Advocacy Coalition (DPAC)
- T1D Exchange
- The diaTribe Foundation
- The France Foundation (TFF)
Target Audience
This educational program is intended for endocrine specialists including endocrinologists, advanced practice professionals (nurse practitioners and physician assistants), nurse and diabetes educators, and primary care providers (MDs, PAs, nurses, clinical pharmacists) who care for patients with diabetes.
Program Goals
The overall goal of IDEA (Innovating Decisions and Empowering Action in Diabetes Management) is to improve understanding of continuous glucose monitoring, report interpretations, and the use of this information to optimize therapeutic management leading to practice transformation and increased shared decision-making.
Instructions for Accessing the Free Material and Pharmacist CPE
Review the free content modules and cases below. Select the "Begin" button to complete your selected topic(s). After completing the home-study course you'll be linked back to the ACCP website to complete a course evaluation and claim the associated continuing pharmacy education for that module or set of cases.
Please note: You must have an accp.com account to login to the webiste, complete the evaluation, and claim the CPE. If you do not have an accp.com account you may create a free account at: https://www.accp.com/signin/register.aspx. You accp.com profile must contain your NABP eProfile ID and birthdate for ACCP to be able to submit the credit to the CPE Monitor® on your behalf.
Program Content
Module 1. Exploring the Evidence: Current Indications for the Use of CGM in Pediatric and Adult Patients
Activity Number: 0217-0000-21-116-H01-P
Contact Hours: 0.5
Activity Type: Knowledge-Based Activity
Presenters:
Gregory P. Forlenza, MD
Assistant Professor, Pediatric Endocrinology
Barbara Davis Center
University of Colorado
Grazia Aleppo, MD, FACE, FACP
Professor of Medicine
Division of Endocrinology, Metabolism, and Molecular Medicine
Feinberg School of Medicine
Northwestern University
Learning Objectives:
- Identify current guidelines for utilization of CGM in the care of patients with diabetes
- Compare and contrast current CGM guideline recommendations
- Anticipate common questions from patients and clinicians related to CGM
- Discuss current and emerging advances in the use of CGM
Begin Module 1
Module 2. CGM: Practical Approaches to Addressing Common Clinical Situations
Activity Number: 0217-0000-21-117-H01-P
Contact Hours: 0.5
Activity Type: Knowledge-Based Activity
Presenters:
David F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Division of Endocrinology, Diabetes, Bone and Mineral Disease
Henry Ford Health System
Richard M. Bergenstal, MD
Executive Director, International Diabetes Center
Adjunct Professor, Department of Medicine
University of Minnesota
Learning Objectives:
- Identify current guidelines for utilization of CGM in the care of patients with diabetes
- Compare and contrast current CGM guideline recommendations
- Anticipate common questions from patients and clinicians related to CGM
- Discuss current and emerging advances in the use of CGM
Begin Module 2
Module 3. Challenges to Continuous Glucose Monitoring (CGM) Adoption and Use
Activity Number: 0217-0000-21-118-H01-P
Contact Hours: 0.5
Activity Type: Knowledge-Based Activity
Presenters:
Diana Isaacs, Pharm.D., BCPS, BC-ADM, BCACP, CDCES
Clinical Pharmacy Specialist
Cleveland Clinic
Anne Peters, MD
Professor, UCSC Keck School of Medicine
Director, USC Clinical Diabetes Program
Learning Objectives:
- Identify current guidelines for utilization of CGM in the care of patients with diabetes
- Compare and contrast current CGM guideline recommendations
- Anticipate common questions from patients and clinicians related to CGM
- Discuss current and emerging advances in the use of CGM
Begin Module 3
Interactive Cases
Activity Number: 0217-0000-21-119-H01-P
Contact Hours: 1.0
Activity Type: Application-Based Activity
Learning Objectives:
- Discuss the limitations of A1C as a marker of diabetes control
- Explain the merits of evaluating time in range and hyperglycemic excursions, as well as A1C
- Describe how glucose monitoring devices facilitate prevention, detection, and prompt treatment of hypoglycemia
- Discuss improved patient outcomes associated with glucose monitoring as well as technological advances that have improved the ease of use of these devices
Choose any 4 cases from the list of 10 below to complete this activity.
Begin Interactive Cases
Interactive Case 1. Nocturnal Hypoglycemia – Pediatric Patient
Presenter:
Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDE
Diabetes Educator, Registered Dietitian, Certified Diabetes Educator
Program Coordinator-Teen Transition Program
The University of Chicago Medicine
Interactive Case 2. Daytime Hypoglycemia – Pediatric Patient
Presenter:
Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDE
Diabetes Educator, Registered Dietitian, Certified Diabetes Educator
Program Coordinator-Teen Transition Program
The University of Chicago Medicine
Interactive Case 3. Hypoglycemia Unaware – Young Adult Patient
Presenter: Wendy McLaughlin, PA-C
Physician Assistant
The Endocrinology Group
Interactive Case 4. Hypoglycemia Unaware – Middle Age Patient
Presenter:
Diana Isaacs, Pharm.D., BCPS, BC-ADM, BCACP, CDCES
Clinical Pharmacy Specialist
Cleveland Clinic
Interactive Case 5. Post-Prandial Hyperglycemia – Elderly Patient
Presenter:
Grazia Aleppo, MD, FACE, FACP
Professor of Medicine
Division of Endocrinology, Metabolism, and Molecular Medicine
Feinberg School of Medicine
Northwestern University
Interactive Case 6. Hypoglycemia All the Time – Pediatric Patient
Presenter:
Gregory P. Forlenza, MD
Assistant Professor, Pediatric Endocrinology
Barbara Davis Center
University of Colorado
Interactive Case 7. Roller Coaster Variability – Young Adult Patient
Presenter: Wendy McLaughlin, PA-C
Physician Assistant
The Endocrinology Group
Arlington, Virginia
Interactive Case 8. No Obvious Pattern – Pediatric Patient
Presenter: Gregory P. Forlenza, MD
Assistant Professor, Pediatric Endocrinology
Barbara Davis Center
University of Colorado
Interactive Case 9. No Obvious Pattern – Elderly Patient
Presenter:
Margaret Kapasi, MS, NP-C
Certified Diabetes Care and Education Specialist
Diabetes Management Program (DMP)
The Emory Clinic
Interactive Case 10. Tight Control in Pregnancy
Presenter:
Carol J. Levy, MD, CDE
Associate Professor
Department of Medicine
Division of Endocrinology, Diabetes, and Bone Disease
Icahn School of Medicine
Mount Sinai Hospital
Begin Interactive Cases
Continuing Pharmacy Education Credit
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). Pharmacists looking for credit will be able to earn up to 2.5 hours of CPE credit by completing all three modules and 4 of the 10 interactive cases listed above and submitting the associated evaluations for each activity by January 31, 2024.
Disclosures
Dr. Aleppo has received research support from Dexcom, Eli Lilly, and Insulet. She has received honoraria from Dexcom and Insulet.
Dr. Bergenstal has received research support, consulted, or has been on a scientific advisory board for Abbott Diabetes Care, Ascensia, DexCom, Hygieia, Johnson & Johnson, Lilly, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi, and United Healthcare.
Dr. Forlenza has received research support from Abbott, Beta Bionics, Dexcom, Medtronic, and Tandem Diabetes. He has served as a consultant for Beta Bionics, Lilly, and Medtronic. He has also served on the speakers bureau for Dexcom, Insulet, and Tandem Diabetes.
Ms. Hess-Fischl has received honoraria from Abbott and Xeris.
Dr. Isaacs has received honoraria from Abbott, Companion Medical, and Dexcom.
Ms. Kapasi has nothing to disclose.
Ms. Kruger has served on advisory boards for Abbott, Boehringher Ingelheim Pharmaceuticals, Inc, Dexcom, Eli Lilly, Janssen, Merck, Novo Nordisk, Pendulum, and Sanofi Aventis. She has also participated on the speakers bureau for Abbott, AstraZeneca, Boehringher Ingelheim Pharmaceuticals, Inc, Dexcom, Eli Lilly, Insulet, Janssen, Novo Nordisk, Valeritas, and Xeris. She has received research support from Abbott, Dexcom, Hemsley Foundation, Lexicon, and Novo Nordisk.
Dr. Levy has received research support from Abbott and Dexcom and has received honoraria from Dexcom.
Ms. McLaughlin has nothing to disclose.
Dr. Peters has participated in advisory boards for Abbott Diabetes Care, Boehringer Ingelheim Pharmaceuticals, Inc, Eli Lilly and Company, Livongo, MannKind, Merck, Novo Nordisk, Sanofi, and Pendulum Therapeutics. She has received research support from Dexcom and vTvTherapeutics. She has also participated in the speakers bureau for Novo Nordisk.
Dr. Enders spouse has received salary from Sanofi-Genzyme.
Dr. Blonde has received honoraria from AstraZeneca, Gilead Sciences, Janssen, Merck and Co, and Novo Nordisk. He has also served as a speaker for Janssen and Novo Nordisk. He has served as a consultant and received research support from Novo Nordisk and Sanofi.
Ms. Brothers has nothing to disclose.
Dr. Galindo has received research support from Novo Nordisk and has served as a consultant for Sanofi, Eli Lilly, Novo Nordisk, and Valeritas.
Ms. Lavin-Tompkins has nothing to disclose.
Dr. Neumiller has received honoraria from the American Diabetes Association.
Dr. Simonson has served on the advisory board for Merck & Co, Inc, and has received grant funding from Abbott Diabetes Care.
Ms. Babbage has nothing to disclose.
Mr. Block has nothing to disclose.
Ms. Burton has nothing to disclose.
Ms. Butts has served on the speakers bureau for Janssen, Novo Nordisk, and Zeris. She has also served on the advisory board for Novo Nordisk.
Ms. Close has nothing to disclose.
Mr. Gershenoff has nothing to disclose.
Ms. Lepkowski has nothing to disclose.
Ms. McClure has nothing to disclose.
Ms. McNeilly has nothing to disclose.
Dr. Michalski has nothing to disclose.
Dr. Vasudevan has nothing to disclose.
Mr. Pereira has nothing to disclose.
Mr. Perry has served as a consultant for Novo Nordisk.
Mr. Peterson has nothing to disclose.
Mr. Swearingen has nothing to disclose.
Ms. Tarbox has nothing to disclose.
Ms. Velcani has nothing to disclose.
Dr. Wilson has nothing to disclose.
Ms. Wolf has nothing to disclose.
Commercial Support
As part of a larger collaboration, the educational program is provided by educational grants from Abbott, AstraZeneca, Dexcom, Janssen, Mannkind, and Novo Nordisk.